Martins AM, et al. (2022). Cannabis-based products for the treatment of skin inflammatory diseases: A timely review. What you need to know (and what we're working to find out) about products containing cannabis or cannabis-derived compounds, including CBD. (2020). Hammell DC, et al. (2016). Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis. Office of the Commissioner. FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy. U.S. Food and Drug Administration. Accessed 5/13/2021. Keep in mind that while any CBD product can have trace levels of THC, full-spectrum CBD will intentionally contain a low level of THC — up to 0.3% in federally legal products. Ingredients

Epidyolex can be prescribed by a specialist for patients with Lennox-Gastaut syndrome and Dravet syndrome (both rare forms of epilepsy). Nabilone for chemotherapy patients A 2022 review notes that CBD may be an option for treating inflammatory skin conditions. However, the authors note that more research is needed to confirm CBD’s effect on skin conditions. Quality matters It would only be considered when other treatments were not suitable or had not helped. Epidyolex for children and adults with epilepsy D'Andre S, McAllister S, Nagi J, Giridhar KV, Ruiz-Macias E, Loprinzi C. Topical Cannabinoids for Treating Chemotherapy-Induced Neuropathy: A Case Series. Integr Cancer Ther. 2021;20:15347354211061739. CBD itself is safe and well tolerated, and it has no risks of abuse or dependence, according to the World Health Organization.CBD cream, which often includes balms and salves, is a topical application of cannabidiol. This cream offers more localized effects rather than systemic ones that edibles or inhalation can provide. A 2018 study mentions how “the endocannabinoid system is distributed throughout the central and peripheral nervous system, it is involved in inflammatory and pain processing, and plays regulatory physiological roles across virtually every organ system.”

Xu DH, et al. (2020). The effectiveness of topical cannabidiol oil in symptomatic relief of peripheral neuropathy of the lower extremities. A Randomised, Double Blind, Placebo Controlled, Parallel Group, Pilot Study of 1:1 and 20:1 Ratio of Formulated GWP42003 : GWP42004 Plus GWP42003 and GWP42004 Alone in the Treatment of Dyslipidaemia in Subjects With Type 2 Diabetes. clinicaltrials.gov. Accessed 5/13/2021. In 2005, Canada approved the use of Sativex, an oromucosal (absorbed in the lining of the mouth) spray with equal proportions of THC and CBD, for the treatment of multiple sclerosis-related central neuropathic pain. In 2007, Canada approved the medicine’s use again for cancer pain that proved unresponsive to other medications.https://journals.lww.com/pain/Abstract/2022/06000/Cannabidiol_treatment_in_hand_osteoarthritis_and.26.aspx